- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00360074
Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation
A Randomised, Controlled, Crossover Study: Treatment With Thyroxin Compared to Thyroxin + Triiodothyronin in Patients With Secondary Hypothyroidism
Study Overview
Status
Intervention / Treatment
Detailed Description
Backround: A normal thyroid function is critical for metabolism, well-being and cognitive function. It is now well accepted that primary subclinical hypothyroidism, characterized by normal circulating thyroid hormones (fT3 and fT4) and elevated TSH, should be treated to improve reduced quality of life and abnormalities of lipid metabolism. In central hypothyroidism (CH) the dose of replacement therapy aims to achieve normal thyroxin (T4) concentrations as defined by appropriate reference populations. Adequate thyroxin treatment is especially challenging, as T4 cannot be titrated according to endogenous TSH levels because of the impaired hypothalamic-pituitary unit. The majority of untreated CH patients show normal (40 %) or elevated TSH levels (35 %) while only a minority has reduced concentrations (25 %) {Faglia, 1979 #1}. These findings are explained by the lack of pulsatile secretion and nocturnal TSH surge, which has been attributed to impaired thyrotroph function in CH patients {Caron, 1986 #2}. Moreover, impaired biological activity of TSH itself due to reduced glycosylation has been described in secondary hypothyroidism.
In a cross sectional study performed in patients with central hypothyroidism, we found elevated cholesterol levels and increased ankle reflex time suggesting subtle hypothyroidism, though fT3 and fT4 serum concentrations were within the normal range. The average dose of thyroxin (T4) applied in these patients with central hypothyroidism was 1.1 µg/kg bw, which is below the average dose recommended in primary hypothyroidism (1.6 µg/kg bw). We hypothesized that these results might indicate suboptimal T4 replacement therapy, not detectable by current laboratory testing.
Hypothesis: To investigate the effects of a body weight adjusted T4 or T3T4 dose on metabolism, well-being and cognitive function.
Study design: Placebo controlled trial in patients with central hypothyroidism following a double blind cross-over design.
Intervention: Three different treatment regimes (5 weeks each) were compared: "CON-T4", empirically chosen, current dose of T4 (1 ± 0.05 μg/kg body weight (bw); "OPT-T4", optimized T4 treatment (1.6 μg/kg bw T4); "T3T4", combination of triiodothyronine (T3, 0.16) and T4 (1.44 μg/kg bw). Biochemical parameters, ankle reflex time and neurocognitive functions were assessed.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Freiburg, Baden-Württemberg, Germany, 79104
- University Hospital Freiburg, Department of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- hypopituitarism of at least 3 axes (TSH plus gonadotropin, somatotropin, corticotropin or ADH deficiency)
- termination of surgical or radiation treatment of pituitary tumors at least six month before study entry
- BMI of 20 - 39.9 kg/m2
- non-smoking status.
Exclusion Criteria:
- history of cardiovascular or pulmonary diseases
- current thyroxin dosage > 1.6 µg/kg bw
- pregnancy
- epilepsy
- cerebrovascular diseases
- nodular goiter
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
well-being
Time Frame: 3 weeks of treatment
|
3 weeks of treatment
|
cognitive function
Time Frame: 3 weeks of treatment
|
3 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
lipid metabolism
Time Frame: 3 weeks of treatment
|
3 weeks of treatment
|
muscle function / ankle reflex time
Time Frame: 3 weeks of treatment
|
3 weeks of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Prof Dr Martin Reincke, MD, former Medical Professor of University Hospital Freiburg
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Endocrine System Diseases
- Thyroid Diseases
- Neoplastic Processes
- Hypothalamic Diseases
- Lipid Metabolism Disorders
- Dyslipidemias
- Pituitary Diseases
- Hypothyroidism
- Neoplasm Metastasis
- Hyperlipidemias
- Hypopituitarism
Other Study ID Numbers
- FH 326/03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipidemias
-
University of BolognaNot yet recruiting
-
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....Not yet recruiting
-
Meir Medical CenterNot yet recruitingHypertriglyceridemiaIsrael
-
Novartis PharmaceuticalsRecruitingHypercholesterolemiaUnited States, Hungary, Mexico, Germany, Colombia
-
Esperion Therapeutics, Inc.RecruitingHypercholesterolemiaUnited States, Spain, Denmark, Canada, Netherlands, Germany
-
Jena University HospitalCharite University, Berlin, Germany; Ruhr University of Bochum; Technische Universität... and other collaboratorsRecruiting
-
Kowa Company, Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
University Health Network, TorontoRecruitingHyperlipidemiasCanada
-
Shahid Beheshti UniversityNational Nutrition and Food Technology InstituteCompleted
Clinical Trials on Thyroxin, Triiodothyronine
-
Northwell HealthThomas and Jeanne Elmezzi FoundationCompletedAtrial FibrillationUnited States
-
Rambam Health Care CampusUnknown
-
University of TartuCompletedThyroid CancerEstonia
-
Copenhagen University Hospital at HerlevCompletedDepression | Quality of LifeDenmark
-
Marion Mertl-RoetzerCompletedMalnutritionGermany
-
I.M. Sechenov First Moscow State Medical UniversityCompleted
-
Cantonal Hospital ZenicaCompletedSeptic Shock | Euthyroid Sick SyndromesBosnia and Herzegovina
-
Seattle Children's HospitalCompletedCongenital Heart DefectsUnited States
-
Michael PortmanCompleted
-
National Cardiovascular Center Harapan Kita Hospital...CRDF Global; Osypka Germany; Dalim BioTech Co., Ltd.CompletedPostoperative; Dysfunction Following Cardiac SurgeryIndonesia